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BACKGROUND: Although pemetrexed, a potent thymidylate synthase (TS) inhibitor, enhances the cytoytoxic effect of platinum
compounds against malignant pleural mesothelioma (MPM), novel combinations with effective targeted therapies are warranted. To
this end, the current study evaluates new targeted agents and their pharmacological interaction with carboplatin–pemetrexed in
human MPM cell lines.
METHODS: We treated H2052, H2452, H28 and MSTO-211H cells with carboplatin, pemetrexed and targeted compounds (gefitinib,
erlotinib, sorafenib, vandetanib, enzastaurin and ZM447439) and evaluated the modulation of pivotal pathways in drug activity and
cancer cell proliferation.
RESULTS: Vandetanib emerged as the compound with the most potent cytotoxic activity, which interacted synergistically with
carboplatin and pemetrexed. Drug combinations blocked Akt phosphorylation and increased apoptosis. Vandetanib significantly
downregulated epidermal growth factor receptor (EGFR)/Erk/Akt phosphorylation as well as E2F-1 mRNA and TS mRNA/protein
levels. Moreover, pemetrexed decreased Akt phosphorylation and expression of DNA repair genes. Finally, most MPM samples
displayed detectable levels of EGFR and TS, the variability of which could be used for patients’ stratification in future trials with
vandetanib–pemetrexed–carboplatin combination.
CONCLUSION: Vandetanib markedly enhances pemetrexed–carboplatin activity against human MPM cells. Induction of apoptosis,
modulation of EGFR/Akt/Erk phosphorylation and expression of key determinants for pemetrexed and carboplatin activity contribute
to this synergistic interaction, and, together with the expression of these determinants in MPM samples, warrant further clinical
investigation.
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Malignant pleural mesothelioma (MPM) is a devastating disease
arising from mesothelial cells that line the thoracic cavity. The
incidence of MPM is increasing throughout the world, and it is
expected to peak around 2015–2020 in Western Europe, as a result
of widespread exposure to its main aetiological factor, asbestos
(Hodgson et al, 2005). There are three distinct histologic subtypes
of MPM, based on the cell microscopic appearance. The epithelial
cell type is the most common, comprising 50–70% of all MPM; it
generally responds the best to treatment, and offers the best
prognosis. By contrast, sarcomatoid mesothelioma represents
7–20% of MPM cases and is the most aggressive subtype. The
biphasic or mixed cell type, as the name implies, is a combination
of elements of both the epithelial and sarcomatoid subtypes and its
prognosis is intermediate. However, current MPM treatment
options do not vary between cell types. Most patients are not
amenable to radical surgery, and the primary goals of treatment in
this setting are prolongation of survival and palliation. The
combination of cisplatin and pemetrexed has recently become the
standard first-line treatment of MPM. This regimen significantly
improved the response rate (RR; 41.3%), time-to-progression
(TTP; 5.7 months), overall survival (OS; 12.1 months) and quality
of life, when compared with cisplatin monotherapy (Vogelzang
et al, 2003). For patients who are unfit to receive cisplatin-
based chemotherapy, pemetrexed alone or in combination with
carboplatin has been proposed as an alternative treatment. In our
phase II study, the pemetrexed–carboplatin combination was well
tolerated and active in 102 MPM patients, showing a disease
control rate (65%), TTP (6.5 months) and OS (12.7 months)
similar to the results achieved with the pemetrexed–cisplatin
regimen (Ceresoli et al, 2006). However, given the dismal
prognosis primarily due to chemoresistance of MPM, the
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evaluation of new therapeutic agents is warranted. A number of
molecular alterations occurring in MPM have been reported,
providing deeper insights into its biology and leading to the
identification of novel druggable targets (Zucali et al, 2011a, b).
Therefore, several novel agents have been, or are currently being
evaluated, including drugs targeted against the epidermal growth
factor receptor (EGFR), vascular endothelial growth factor (VEGF)
and different kinases involved in cancer proliferation (Kindler, 2008).
Treatment of MPM patients with the EGFR-tyrosine kinase
inhibitors (TKIs) gefitinib and erlotinib failed to improve
response/survival (Govindan et al, 2005; Garland et al, 2007).
Similarly, phase II studies of the antiangiogenic agents SU5416,
vatalanib, thalidomide and sorafenib demonstrated only modest
activity as monotherapy, hence being comparable to other single
agents in this disease (Kindler, 2008). The lack of the expected
positive outcome may have been caused by the lack of patient
selection, due to the absence of predictive markers for response to
targeted agents in MPM, or by the lack of the right chemotherapy
cornerstone for the addition of these targeted therapies. More
recently, a randomised phase II trial evaluating the addition of the
anti-VEGF antibody bevacizumab to gemcitabineþ cisplatin
reported a slight increase in progression-free survival (PFS), and
patients with VEGF levels less than the median had longer PFS and
OS when treated with bevacizumab, suggesting that antiangiogenic
therapy could benefit subgroups of MPM patients (Karrison et al,
2007). Several studies of bevacizumab as well as other new
biological agents in combination with pemetrexed and platinum
are ongoing (http://www.clinicaltrials.gov). However, the following
points should be considered: (1) targeted therapy in combination
with cytoreductive chemotherapy should not be given to all
patients irrespective of their characteristics, but only to individuals
presenting the molecular target of the therapy and in whom these
targets are crucial for cancer cell survival (Gutierrez et al, 2009)
and (2) the prospects of integrating targeted agents with cytotoxic
drugs should include the search of optimal cytoreduction based on
molecular mechanisms underlying synergistic drug interaction
(Giovannetti et al, 2008). Therefore, preclinical studies investigat-
ing new combinations of targeted agents with cytotoxic chemo-
therapy and deciphering the molecular mechanisms of drug
interaction as well as potential markers of drug activity are
urgently needed.
The aim of the current study was to evaluate the molecular and
cellular characteristics underlying the synergistic cytotoxicity
observed between new targeted agents and the carboplatin–
pemetrexed combination through an in vitro assessment of their
pharmacologic interaction. We found a potent synergistic inter-
action between carboplatin–pemetrexed and the EGFR/VEGFR-
2/RET inhibitor vandetanib against four human MPM cell lines.
Several factors including apoptosis induction, modulation of
phosphorylation and expression of critical gene products involved
in drug activity contributed to this synergistic interaction. Their
expression was also validated in a panel of MPM biopsies and
might therefore lead to the selection of individual patients for
personalised therapies.
MATERIALS AND METHODS
Cell lines and drugs
Four human MPM cell lines (Table 1), NCI-H28 and NCI-H2052
(sarcomatoid), NCI-H2452 (epithelioid) and MSTO-211H (biphasic),
were obtained from ATCC (Manassas, VA, USA) and tested within
the last 6 months by morphology check and growth curve analysis
according to the Cell Line Verification Recommendations (ATCC-
Technical-Bulletin#8, 2008).
Cells were cultured in DMEM, containing 2mM L-glutamine,
supplemented with 10% heat-inactivated fetal bovine serum, and
1% penicillin–streptomycin (10 000Uml–1), at 37 1C under an
atmosphere of 5% CO2. The cells were maintained in 75 cm
2
culture flasks (Greiner-Bio-One, Frickenhausen, Germany) and
harvested with trypsin-EDTA (Invitrogen, Paisley, UK) at their
exponential phase of growth phase.
In vitro studies were carried out using the drugs detailed in
Table 2.
Analysis of mutations and polymorphisms in determinants
of drug activity
The MPM cells were characterised for EGFR and k-Ras mutations.
Furthermore, we evaluated the AKT1-SNP4-G/A (rs#1130233)
polymorphism, related to gefitinib resistance (Giovannetti et al,
2010), as well as polymorphisms that may influence pemetrexed
sensitivity, such as the methylenetetrahydrofolate reductase
(MTHFR) MTHFR-C677T (rs#1801133) and the reduced folate
carrier (RFC) RFC-G80A (rs#1051266), and carboplatin activity,
such as the DNA repair systems excision-repair cross-complement-
ing-group-1 (ERCC1), and xeroderma-pigmentosum group-D
(XPD) polymorphisms ERCC1-C118T (rs#11615), XPDAsp312Asn
(rs#1799793) and XPDLys751Gln (rs#13181). DNA was isolated
using miniDNA-kit (Qiagen, Hilden, Germany). DNA yields and
integrity were checked at 260–280 nm with NanoDrop-1000-
Detector (NanoDrop-Technologies, Wilmington, DE, USA).
Nested PCR to amplify EGFR (exons 18–21) and K-Ras (exons
1–2) and sequencing of PCR products on ABI-3100 genetic
analyser (Applied Biosystems, Foster City, CA, USA) was
performed as described (Giovannetti et al, 2010). All polymorph-
isms were evaluated with Taqman-probes-based assays using the
ABIPRISM-7500HT instrument (Applied Biosystems). These PCR
reactions were performed using 20 ng of DNA (Giovannetti et al,
2010).
Table 1 Genetic background of drug activity determinants in MPM cells
NCI-H2052 NCI-H2452 NCI-H28 MSTO-211H
Polymorphisms
AKT1-SNP4 G/G A/A G/G G/G
MTHFR-C677T T/T C/T C/C C/T
RFC-A80G A/A A/G A/A A/A
ERCC1-C118T C/T T/T C/T C/T
XPD-Asp312Asn Asp/Asn Asp/Asp Asp/Asp Asp/Asn
XPD-Lys751Gln Lys/Gln Lys/Lys Lys/Lys Lys/Gln
mRNA expressiona
EGFR 30.6±2.6 75.8±6.1 61.9±5.0 45.6±3.3
VEGFR-2 0.4±0.1 2.7±1.0 nd 0.9±1.3
RET 0.5±0.1 1.1±0.2 nd nd
ERCC1 7.7±0.8 0.3±0.1 0.6±0.1 2.3±0.4
XPD 22.4±3.7 11.4±1.9 8.9±1.4 17.5±1.8
TS 57.7±5.9 31.3±3.7 106.6±9.4 76.7±6.3
E2F-1 18.3±2.1 13.0±0.9 54.3±6.2 25.7±2.8
DHFR 48.2±3.9 22.7±1.2 27.5±4.5 21.0±2.0
GARFT 1.1±0.1 1.8±0.2 9.8±0.8 3.3±0.5
RFC 8.4±2.5 1.3±0.1 1.4±0.3 9.5±0.8
FPGS 53.7±5.6 11.1±1.7 23.5±2.3 55.2±1.6
Abbreviations: DHFR¼ dihydrofolate reductase; EGFR¼ epidermal growth factor
receptor; ERCC1¼ excision-repair cross-complementing-group-1; FPGS¼ folyl-poly-
glutamate synthetase; GARFT¼ glycinamide ribonucleotide formyltransferase;
MPM¼malignant pleural mesothelioma; MTHFR¼methylene-tetrahydrofolate
reductase; nd¼ not detectable; RFC¼ reduced folate carrier; TS¼ thymidylate
synthase; Wt¼wild-type; XPD¼ xeroderma-pigmentosum group-D; VEGFR¼ vas-
cular endothelial growth factor receptor; cDNA¼ complementary DNA. aRelative
mRNA expression levels were expressed in arbitrary units and normalised to b-actin,
using a method with standard curves derived from serial dilutions from a reference
cDNA obtained from Quantitative-PCR Human-Reference Total-RNA.
Vandetanib, pemetrexed and carboplatin in MPM
E Giovannetti et al
1543
British Journal of Cancer (2011) 105(10), 1542 – 1553& 2011 Cancer Research UK
T
ra
n
sl
a
ti
o
n
a
l
T
h
e
ra
p
e
u
ti
c
s
Cytotoxicity assays
Cell growth inhibitory effects of the drugs (0.001–50 mM, 72-h
exposure) were studied using MTT and SRB assays. For this
purpose, cells were plated at 5 104 cells per well and growth
inhibition was expressed as the percentage of control (vehicle-
treated cells) absorbance (corrected for absorbance before drug
addition). The 50% inhibitory concentration of cell growth (IC50)
was calculated by non-linear least squares curve fitting (GraphPad
PRISM, Intuitive Software for Science, San Diego, CA, USA).
Drug combination studies
Several studies showed a more efficient interaction when cytotoxic
agents are given before or simultaneously with EGFR-TKIs
(Morelli et al, 2005; Bianco et al, 2006; Van Schaeybroeck et al,
2006; Giovannetti et al, 2008). Therefore, combination studies were
focused on simultaneous treatment with the compounds used in
the clinical setting (i.e., pemetrexed and carboplatin, alone and in
combination) and vandetanib, the most potent targeted compound
in the previous cytotoxicity studies. Vandetanib was also chosen
for its potential to affect several molecular mechanisms that might
sensitise cells to the cytotoxic activity of pemetrexed and
carboplatin (e.g., apoptosis induction, and modulation of key
drug determinants), as assessed in the experiments detailed below.
Each combination was tested in at least six different concentra-
tions, using a constant ratio calculated with respect to drug IC50s.
The cytotoxicity of these combinations was compared with the
cytotoxicity of each drug alone using the combination index (CI),
where CIo0.9, CI¼ 0.9–1.1 and CI41.1 indicated synergistic,
additive and antagonistic effects, respectively (Bianco et al, 2006).
Data analysis was carried out using CalcuSyn software (Biosoft,
Oxford, UK).
Cell-cycle analysis
Cell-cycle modulation induced by treatments at IC50s for 72 h was
studied by propidium iodide (PI) staining using a FACScan
(Becton Dickinson, San Jose´, CA, USA). Data analysis was carried
out with CELLQuest (Becton Dickinson), while cell-cycle distribu-
tion was determined using Modfit software (Verity-Software,
Topsham, ME, USA).
Evaluation of apoptosis
Single drugs and their combinations were also characterised for
their ability to induce apoptosis, as detected after 72-h drug
exposure at IC50s. Apoptosis was determined with the FITC-
AnnexinV-Apoptosis kit (Becton Dickinson) according to the
manufacturer’s protocol. Cells were stained by the addition of both
5 ml AnnexinV-FITC and 10 ml PI solution. The samples were
analysed with a FACScan and data analysis was carried out with
FACSdiva software (Becton Dickinson).
Further studies were performed with bisbenzimide-HCl staining,
as described (Bianco et al, 2006).
RT–PCR
Gene expression of the following key determinants of drug
sensitivity was assessed by RT–PCR: EGFR (NM_005228.3),
VEGFR-2 (NM_002253.2), RET (NM_020363.4) ERCC1
(NM_001983), XPD (NM_000400), thymidylate synthase (TS;
NM_0010711), dihydrofolate reductase (DHFR; NM_000791),
glycinamide ribonucleotide formyltransferase (GARFT;
NM_000819), RFC (NM_194255.1) and folyl-polyglutamate synthe-
tase (FPGS; NM_004957). Since previous studies reported a strong
correlation between expression levels of TS and its upstream
transcriptional regulator E2F-1 (Huang et al, 2007), and other
studies showed that EGFR-TKIs affected E2F-1 (Kobayashi et al,
2006; Suenaga et al, 2006), we also evaluated the expression of
E2F-1 (NM_005225.2).
Conversely, we did not evaluate the expression of the folate
receptor a (FRa), which was not correlated with the sensitivity to
pemetrexed in MPM cells and samples (Nutt et al, 2010).
However, we studied whether single drugs and their combina-
tions, at IC50s, modulated expression of ERCC1, XPD, TS and
E2F-1. RNA was extracted by the QiaAmp RNA mini-Kit (Qiagen),
and reverse transcribed. Primers and probes were obtained from
Applied Biosystems (Giovannetti et al, 2008; Nannizzi et al, 2010).
Amplification data were normalised to b-actin, and quantifica-
tion of gene expression was performed using standard curves
obtained with dilutions of cDNA from Quantitative-PCR Human-
Reference Total-RNA (Stratagene, La Jolla, CA, USA). Results of
basal expression analysis of single or combined genes (e.g.,
FPGSRFC/(TSDHFRGARFT)) were related to chemosensi-
tivity, while quantification of gene expression in treated cells was
performed using the DDCT calculation, where CT is the threshold
cycle. The amount of target gene, normalised to b-actin, and
relative to the calibrator (untreated cells), was expressed as 2DDCT
and reported as percent variation.
Western blot analysis
Single drugs and their combinations, at IC50s, were also studied for
their ability to modulate protein expression of TS. After 72-h
exposure, cell pellets were collected and lysed, and 20 mg of
proteins were separated on SDS–PAGE gel, followed by blotting
onto a nitrocellulose membrane. The membrane was pre-incubated
in blocking buffer (0.5% milk powder, 0.5% BSA in TBS-T) for 1 h,
while the primary polyclonal TS antibody (1 : 1000, kindly
Table 2 Drugs used and their IC50 values (mM) in MPM cells
Drugs Drug targets H2052 H2452 H28 MSTO-211H
Carboplatin DNA 5.30±1.02 2.69±0.71 10.50±2.59 0.51±0.12
Pemetrexed TS, DHFR, GARFT 0.07±0.01 2.82±0.17 10.96±2.46 0.02±0.01
Vandetanib EGFR, VEGFR-2/3, RET 1.07±0.04 3.52±1.13 0.32±0.07 1.42±0.03
Sorafenib Raf, PDGF, VEGFR-2/3 6.09±1.78 14.59±4.58 10.22±1.93 3.18±0.27
Gefitinib EGFR 5.22±1.53 4.83±1.24 3.99±1.28 4.91±1.04
Erlotinib EGFR 5.55±1.28 5.26±1.29 3.92±1.06 5.48±1.93
Enzastaurin PKCb, VEGF 11.56±3.82 10.07±2.96 8.11±2.19 10.92±2.59
ZM447439 Aurora kinase B 12.73±3.49 10.40±3.27 11.12±4.02 9.65±3.06
Abbreviations: DHFR¼ dihydrofolate reductase; DMSO¼ dimethyl sulfoxide; EGFR¼ epidermal growth factor receptor; GARFT¼ glycinamide ribonucleotide formyltransferase;
MTT¼ 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PDGF¼ platelet-derived growth factor; PKCb¼ protein kinase Cb; RET¼ rearranged during transfection;
SRB¼ sulforhodamine B; TS¼ thymidylate synthase; VEGFR¼ vascular endothelial growth factor receptor; MPM¼malignant pleural mesothelioma. Notes: The drugs were
dissolved in DMSO or sterile water and diluted in culture medium before use. IC50 concentrations were calculated as mean values±s.e.m. of at least three independent MTT or
SRB experiments.
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provided by Dr GW Aheme) was added overnight, at 4 1C. After
washing in TBS-T, the blots were incubated for 1 h with anti-rabbit
horseradish peroxidase-labelled secondary antibodies (1 : 2000,
DakoCytomation, Glostrup, Denmark). Antibody binding was
detected using enhanced chemoluminescence. Densitometric
analysis of the images captured on the VersaDoc3000 instrument
(Bio-Rad, Philadelphia, PA, USA) was performed with the
Kontron-Analysis-Image software (Kontron-Electronik, Munich,
Germany).
Evaluation of TS in situ activity
To evaluate the possible modulation of TS activity, we determined
its potential inhibition in intact cells, after 24-h drug exposure at
IC50s. For this purpose, cells were plated at 0.25 106 cells in six-
well plates. After 22 h of drug treatment, (5-3H)-deoxycytidine
(0.3mM, final specific activity 1.6 Cimmol– 1) was added. After
uptake, (5-3H)-deoxycytidine was phosphorylated to (5-3H)-
dCMP, which was deaminated to (5-3H)-dUMP, which was in
turn methylated to dTMP releasing 3H2O. Production of 3H2O was
measured by collecting medium samples after 2 h and counting of
the radioactivity as described (Giovannetti et al, 2008).
EGFR, ERK1/2 and Akt ELISA phosphorylation assays
To study the effect of drug treatments on the activation of EGFR,
as well as of ERK1/2 and Akt, MPM cells were exposed for 2 h to
IC50s of single drugs and their combinations after pulse stimula-
tion with EGF (10 ngml–1), as described (Janmaat et al, 2006).
After protein extraction from cell pellets, EGFR phosphorylation at
the tyrosine residue at position 1173 (EGFR [pY1173]), dual
phosphorylation of ERK2 at threonine-185 and tyrosine-187 (ERK2
[pTpY185/187]) and ERK1 at threonine-202 and tyrosine-204
(ERK1 [pTpY202/204]) and Akt phosphorylation at serine-473
(Akt [pS473]) were evaluated with specific ELISA assays
(Invitrogen), and normalised, respectively, to the total EGFR,
ERK1/2 and Akt, as well as to protein content (Bianco et al, 2006).
ELISA measurement of VEGF levels
Measurement of VEGF levels in medium was performed after
exposing 1 105 cells to IC50 concentrations of the drugs, alone or
in combination. Samples of the medium (200 ml) were taken after
24 h, centrifuged for 20min at 1000 g and VEGF levels were
measured using a specific kit (R&D Diagnostics, Minneapolis, MN,
USA). A calibration line was included in each plate.
PCR and immunohistochemistry in MPM tissues
RNA was isolated from 44 MPM paraffin-embedded sections using
the RecoverAll-Total-Nucleic-Acid Isolation kit (Ambion, Applied
Biosystems) from chemonaive patients. RNA quality was checked
by 260–280 nm measurements and PCR analysis of TS and EGFR
was performed as described above. Immunohistochemical studies
were carried out using specific monoclonal antibodies for EGFR
(Neomarkers, Union City, CA, USA; diluted to a final concentra-
tion of 4 mgml–1), and TS (clone 106, dilution 1 : 100; Dako). To
enhance the immunoreactivity, standard 2 mm thick sections were
submitted to antigen retrieval after deparaffination and rehydra-
tion. The endogenous peroxidase activity was blocked with 3%
hydrogen peroxidase for 30min, and the primary antibody
incubation was carried out for 1 h at room temperature. Negative
controls were obtained replacing the primary antibodies with
buffer. The immune reaction was revealed with a biotin-free
detection system based on a dextran chain linked to the secondary
antibody and peroxidase (EnVision, DakoCytomation). Staining
was performed with 3,30-diaminobenzidine (DAB; DakoCytoma-
tion) as a chromogen and sections were counterstained with
haematoxylin. Similar to previous studies (Destro et al, 2006;
Zucali et al, 2011a, b), the results were interpreted using a system
based on staining intensity and on the number of stained cells.
Endothelial cells from tonsils served as external positive controls,
whereas lymphocytes were used as intra-tumoural positive control.
Statistical analysis
All experiments were performed in triplicate and repeated at least
twice. Data were expressed as mean values±s.e. and analysed by
Student’s t-test or ANOVA followed by the Tukey’s multiple
comparison test. The Pearson/Spearman correlation and regres-
sion analysis were used to demonstrate the relationship between
gene expression profile and chemosensitivity, as well as between
erlotinib and gefitinib cytotoxic activity, TS mRNA and protein
expression and modulation of E2F-1 and TS mRNA expression.
The level of significance was Po0.05.
RESULTS
Genetic background of the human MPM cell lines
Genomic DNA and RNA extracted from the various MPM cells
were used to detect mutations, polymorphisms and mRNA
expression levels of genes potentially affecting drug activity, as
depicted in Table 1. No mutations were detected in EGFR and Ras,
as previously reported in the Cosmic data bank for cells and
mesothelioma patients (http://www.sanger.ac.uk/genetics/CGP/
cosmic/).
Growth inhibition studies and correlation with genetic
background
A dose-dependent inhibition of tumour cell growth was observed
with all drugs studied using four established MPM cell lines
(Table 2). The IC50 values ranged from 0.021±0.003 (pemetrexed
in MSTO-211H cells) to 14.59±4.58mM (sorafenib in H2452 cells),
and most compounds (gefitinib, erlotinib, enzastaurin and
ZM447439) displayed similar growth inhibitory activities in these
tumour cell lines. A strong correlation was found between cellular
sensitivity to erlotinib and gefitinib (R2¼ 0.981, P¼ 0.018).
MSTO-211H cells harbouring the XPD-Asp312Asn/Lys751Gln
genotypes were the most drug-sensitive cells, whereas H28 cells
bearing the XPD-Asp312Asp/Lys751Lys genotypes were the most
inherently drug resistant to both carboplatin and pemetrexed.
However, no clear relationship could be established between
polymorphisms and chemosensitivity.
Basal mRNA levels of ERCC1 and XPD, as well as TS, DHFR,
GARFT, FPGS and RFC were also evaluated for their
possible correlation with carboplatin and pemetrexed sensitivities,
respectively.
The lower chemosensitivity of the H28 cells to pemetrexed is
likely related to the higher expression levels of genes encoding TS
and GARFT, relative to other tumour cell lines. In addition, this
cell line displayed a low level of RFC expression, which may be
associated with a diminished uptake of pemetrexed, despite an
intermediate expression of FPGS. In contrast, drug-sensitive
NCI-H2052 cells exhibited high RFC and FPGS expression but
low TS levels. However, when statistically examined individually,
none of the target genes was found to be related to cell sensitivity,
whereas a good correlation was observed between the ratio of
FPGSRFC/(TSDHFRGARFT) and pemetrexed IC50 values
(R2¼ 0.928; P¼ 0.020). The targeted cytotoxic compound display-
ing the most potent growth inhibitory activity among the four cell
lines was vandetanib (IC50 range, 0.32±0.07 (H28) to
3.52±1.13mM (H2452)), which was therefore further evaluated in
combination with carboplatin and pemetrexed.
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Pharmacological interaction
Since the CI method recommends a ratio of concentrations at
which drugs are equipotent, combination studies were performed
using fixed ratios with IC50 values for carboplatin and pemetrexed.
Experiments were performed in H28 and H2452 cells, which were
relatively resistant to both the antiproliferative effects of carbo-
platin and pemetrexed, but characterised by the lowest and the
highest IC50 value for vandetanib, respectively. Furthermore,
although two cell lines cannot represent the heterogeneity and
complexity seen in human MPM, the two cell lines included in
these studies were representative of the most common hystotypes
(epithelioid and sarcomatoid), comprising 485% of all MPM
cases, as well as of the prognostic extremes.
For the triple simultaneous combination, we used vandetanib at
a fixed IC25 concentration. Both the carboplatin and vandetanib
combinations reduced the IC50 values of pemetrexed in the studied
cell lines. Similarly, vandetanib significantly reduced the IC50
values of carboplatin, and the triple combination of carboplatin,
pemetrexed and vandetanib displayed the most potent cytotoxic
effect. Representative growth inhibition curves for H28 cells are
shown in Figure 1A. Multiple drug-effect analysis revealed strong
synergistic effects in all the treatments. For example, the CI plots
(Figure 1B) in H28 cells showed a clear synergistic interaction at
the more relevant FA values in all the three doublet combinations
(X25%). The average CI values for all the combinations in the two
MPM cell lines are summarised in Figure 1C. To explore the
mechanisms underlying these synergistic drug interactions, we
performed several biochemical analyses (cell-cycle analysis,
apoptosis detection, western blot analysis), as detailed below.
Most of these analyses were performed after 72-h drug exposure,
while the phosphorylation of EGFR, ERK1/2 and Akt was evaluated
after 2 h, in agreement with previous studies showing that the
dynamics of protein phosphorylation was optimally detected at
early time points (Janmaat et al, 2006). Similarly, the measurement
of VEGF and TS levels was performed after 24-h exposure, which
represents the optimal exposure time for these assays (Tekle et al,
2008).
Cell-cycle alterations and induction of apoptosis
Flow cytometric DNA analysis was performed to evaluate the effect
of carboplatin, pemetrexed, vandetanib and their combinations on
cell-cycle distribution and to determine whether or not their cell-
cycle alterations might provide clues to optimise drug scheduling.
All these agents were able to affect the cell-cycle parameters of all
four MPM cell lines studied (Table 3).
Carboplatin induced a slight cell-cycle arrest in the G2-phase in
all cell lines, ranging between þ 4.7% and þ 7.9% in MSTO-211H
and H28 cells, respectively. In contrast, pemetrexed increased the
fraction of cells in the S-phase; this increment was most
pronounced in MSTO-211H and H2052 (1.6- and 1.9-fold,
respectively). Vandetanib increased the fraction of cells at the
G1-phase, ranging from þ 4.3% to 13.5% in H28 and MSTO-211H
cells, respectively. Remarkably, all combinations markedly in-
creased the S- and G2-phase population compared with controls. In
particular, carboplatinþ vandetanib combination resulted in a
lower increase in S-phase population, since more cells accumulated
in G2-/M-phase. In contrast, all the combinations including
pemetrexed mostly increased the percentage of cells in S-phase.
All treatments induced cell death, as shown by the presence of a
cell population with sub-G1 DNA content in the FACS analysis,
which was confirmed by AnnexinV assay and fluorescence
microscopy analysis of typical apoptotic morphology after staining
with the intercalating DNA dye bisbenzimide. The combinations of
two drugs significantly increased the apoptotic index with respect
to controls, up to 17.3% in MSTO-211H cells after pemetrex-
edþ vandetanib exposure, and the triple combination was more
active and caused a significant induction of apoptosis when
compared with both controls and pemetrexed-treated or carbo-
platin-treated cells in all cell lines.
EGFR, ERK1/2 and Akt phosphorylation assays
The analysis of the EGFR pathway was performed in H28 and
H2452 cells. Expectedly, vandetanib significantly suppressed EGFR
phosphorylation at the tyrosine residue pY1173, with percentages
of reduction of phospho-EGFR ranging up to 74.3% in H28 cells.
Conversely, pemetrexed enhanced pY1173-EGFR levels. The
pemetrexedþ carboplatin combination also significantly increased
pY1173-EGFR levels, whereas all drug combinations including
vandetanib reduced the phosphorylation status of EGFR, albeit to a
lower extent than vandetanib alone (Figure 2A).
Since EGFR signalling is transduced mainly through the Akt and
ERK1/2 kinase pathways, we also investigated the phosphorylation
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Figure 1 Cytotoxicity and pharmacological interaction of carboplatin,
pemetrexed and vandetanib. (A) Representative curves of growth
inhibitory effects of carboplatin, pemetrexed, vandetanib and their
combinations in H28 cells (for the combinations drug concentrations on
the X-axis are referred to pemetrexed). (B) CI fraction affected (FA) plots
of the carboplatin–pemetrexed, carboplatin–vandetanib, pemetrexed–
vandetanib and carboplatin–pemetrexed–vandetanib combinations in
H28 cells. (C) Mean CI values of all the combinations in H28 and
H2452 cells. CI values at FA of 0.25, 0.5, 0.75 and 0.9 were averaged for
each experiment, and this value was used to calculate the mean between
experiments, as described in the Materials and Methods section. Points and
columns, mean values obtained from three independent experiments;
bars, s.e.m.
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status of Akt and ERK1/2. Phospho-ERK1/2 levels were markedly
reduced (450%) by vandetanib in H28 cells, while a lower degree
of inhibition (B20%) was detected in H2452 cells. In contrast,
pemetrexed and carboplatin exposure had a negligible effect on
ERK1/2 phosphorylation, while a slight reduction of phospho-
ERK1/2 was detected with all drug combinations. Akt phosphor-
ylation was significantly decreased (450%) by vandetanib in
H28 cells, whereas the inhibition was of about 35% in H2452
cells. Similar results were obtained after exposure to both
pemetrexed and carboplatin. Akt phosphorylation was additionally
reduced by the simultaneous combination, with a degree of
inhibition up to 80.4% and 65.7% after the triple combination
of carboplatinþ pemetrexedþ vandetanib in H28 and H2452 cells,
respectively.
Modulation of TS and E2F-1 mRNA and TS protein
expression
To gain further insight into the molecular mechanisms involved in
regulating drug interactions, we examined alterations in the
expression of TS, the primary target of pemetrexed. H2452 and
H28 cells treated with vandetanib had a 2.3- and 4.8-fold decrease
in TS mRNA expression (Figure 2B). In contrast, pemetrexed
significantly increased TS mRNA expression in both cell lines.
However, all drug combinations including vandetanib, not only
prevented the pemetrexed-induced increase, but rather decreased
TS expression. Similarly, both vandetanib and its combinations
significantly reduced E2F-1 mRNA levels in MPM cells, and the
modifications in TS and E2F-1 expression levels after vandetanib
and vandetanib combinations were correlated (R2¼ 0.87).
Thymidylate synthase expression was also studied at the protein
level using western blot analysis in H2452 and H28 cells
(Figure 2C). This analysis revealed a marked induction in
pemetrexed-treated H2452 cells, while vandetanib repressed TS
expression, with barely detectable levels observed in protein
extracts isolated from H28 cells. A reduction in TS expression was
also detected in cells treated with cytotoxic drug combinations
containing vandetanib.
Modulation of TS activity
Since protein expression of TS is not necessarily predictive of the
cellular catalytic activity of TS, we hence evaluated TS activity by
the TS in situ assay, in which intact H28 (Figure 2D) and H2452
cells were used. This assay showed a similar inhibition of TS by
pemetrexed and vandetanib in both cell lines. Most interestingly,
the combination of pemetrexed and vandetanib almost completely
blocked TS activity, and statistical analysis revealed a significant
reduction with respect to that observed after pemetrexed exposure
(Po0.037 and Po0.027 in H28 and H2452 cells, respectively).
Alterations of ERCC1 and XPD mRNA expression
Drug-treatment-dependent alterations in gene expression levels of
ERCC1 and XPD in H28 cells are shown in Figure 2B. Carboplatin
had a negligible effect on XPD expression, but caused a significant
increase in ERCC1 levels, up to 2.2- and 2.0-fold in H28 and H2452
cells, respectively. In contrast, pemetrexed significantly reduced
ERCC1 in both cell lines. Pemetrexed also decreased XPD
expression, up to 62.6% in H2452 cells. Similarly, vandetanib
significantly decreased both ERCC1 and XPD expression. Finally,
ERCC1 and XPD levels were reduced by all drug combinations in
both cell lines.
Table 3 Cell-cycle modulation and apoptotic index
Cells Treatment G0/G1 phase (%) S phase (%) G2/M phase (%) Apoptotic index (%)
NCI-H2052 Control 69.9±4.2 12.8±1.4 17.3±2.0 1.3±0.2
Carboplatin 64.2±7.1 13.6±0.9 22.2±1.4 5.0±0.4
Pemetrexed 70.3±6.3 24.5±2.5 5.2±0.2 4.5±0.7
Vandetanib 78.2±8.5 9.3±0.8 12.5±0.2 6.4±0.2
Pemetrexed+carboplatin 63.2±6.9 15.8±3.7 21.0±2.5 11.3±1.9*
Pemetrexed+vandetanib 65.7±4.8 17.9±3.2 16.4±1.6 12.6±2.5*
Carboplatin+vandetanib 60.4±5.6 16.8±0.3 22.8±0.9 13.1±3.3*
Pemetrexed+carboplatin+vandetanib 58.8±4.1 19.2±1.1 22.0±3.0 19.4±2.8**
NCI-H2452 Control 75.3±7.8 17.3±4.1 7.4±0.5 1.1±0.3
Carboplatin 72.9±5.3 14.8±1.2 12.3±1.7 4.1±1.2
Pemetrexed 69.5±6.4 24.0±2.2 6.5±0.4 3.5±0.4
Vandetanib 80.4±7.2 10.9±1.1 8.7±0.9 3.3±0.5
Pemetrexed+carboplatin 52.6±4.9 32.8±4.1 14.6±1.1 9.5±2.6*
Pemetrexed+vandetanib 47.0±4.4 37.2±4.0 15.8±1.2 10.7±1.9*
Carboplatin+vandetanib 54.9±5.7 29.6±2.1 15.5±1.0 11.4±2.3*
Pemetrexed+carboplatin+vandetanib 47.2±3.8 37.6±3.1 15.2±0.9 20.5±4.1**
NCI-H28 Control 69.9±7.1 12.8±0.3 17.3±1.7 1.3±0.2
Carboplatin 60.3±5.1 14.5±1.1 25.2±2.2 3.0±1.1
Pemetrexed 66.2±8.9 16.7±1.1 17.1±1.5 4.5±1.0
Vandetanib 74.2±4.1 7.5±0.9 18.3±1.6 7.7±1.3
Pemetrexed+carboplatin 50.0±4.6 28.6±3.1 21.4±2.3 11.2±1.2*
Pemetrexed+vandetanib 42.8±3.5 19.0±2.0 38.2±3.1 13.5±3.3*
Carboplatin+vandetanib 46.1±4.8 14.7±1.3 39.2±2.6 11.1±2.8*
Pemetrexed+carboplatin+vandetanib 51.1±5.7 26.9±3.2 22.0±4.0 18.2±1.8**
MSTO-211H Control 57.5±6.1 19.2±1.1 23.3±3.0 1.5±0.2
Carboplatin 50.2±5.1 21.8±2.2 28.0±2.9 4.4±0.3
Pemetrexed 56.1±5.5 31.4±3.0 12.5±1.1 10.1±2.2
Vandetanib 71.0±6.8 10.7±1.3 18.3±2.1 4.2±0.7
Pemetrexed+carboplatin 40.3±4.0 34.5±3.1 25.2±2.6 15.1±2.5*
Pemetrexed+vandetanib 28.7±2.6 32.9±4.1 38.4±3.1 17.3±3.1*
Carboplatin+vandetanib 30.3±2.9 28.7±1.3 41.0±0.9 15.9±2.7*
Pemetrexed+carboplatin+vandetanib 27.5±3.1 36.1±4.5 36.4±2.7 26.4±3.3**
*Po0.05 with respect to control cells, **Po0.05 with respect to pemetrexed+carboplatin-treated cells.
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Modulation of VEGF expression
Since vandetanib has been reported to have an impact on plasma
VEGF levels, we evaluated the expression of VEGF levels in both cells
and culture medium. Vandetanib neither affected VEGF mRNA levels
nor VEGF secretion into the growth medium. On the other hand,
pemetrexed and carboplatin induced a slight increase in VEGF mRNA
expression (Figure 2B) and VEGF protein in the cell culture medium
(data not shown). However, all combinations had a negligible effect
on VEGF expression in both cell lines (data not shown).
Expression of EGFR and TS in specimens from MPM
patients
Epidermal growth factor receptor and TS mRNA and protein
expression was detectable in most tumour specimens. Representative
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Figure 2 Effects of carboplatin, pemetrexed, vandetanib and their combinations on critical determinants of drug activity in H28 cells. (A) Modulation of
phosphorylation of EGFR and downstream molecules ERK1/2 and Akt. (B) Modulation of TS, E2F-1, ERCC1, XPD and VEGF mRNA as determined by real-time
RT–PCR. (C) Representative blots illustrating the modulation of TS protein expression. (D) Modulation of TS activity. Columns, mean values obtained from
three independent experiments; bars, s.e.m. *Significantly different from controls (Po0.05). #Significantly different from pemetrexed-treated cells (Po0.05).
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results from staining of paraffin-embedded MPM tissue samples for
EGFR, and TS are shown in Figure 3A; the expression values
observed across the cohort of patients subjected to transcript level
analysis (Figure 3B), were similar to the expression levels observed
in the MPM cell lines. A significant correlation was found between
mRNA and protein levels (Figure 3C), whereas no statistical
associations were found between EGFR and TS, as well as between
EGFR and TS levels and tumour histology/stage/grade.
DISCUSSION
The present study demonstrates that vandetanib is the targeted
antitumour agent displaying the most potent growth inhibitory
effects in a panel of human MPM cell lines characterised by
distinct molecular properties. Limited published preclinical
research focusing on this issue reported similar cytotoxic activity
in H28, MSTO-211H and H226 MPM cell lines (Nutt et al, 2009), as
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Figure 3 Immunohistochemistry and PCR of MPM samples. (A) Representative examples (original magnification,  40) from staining of paraffin-
embedded MPM samples (36 epithelioid, 7 biphasic and 1 sarcomatoid) for TS (right panels) and EGFR (left panels). TS showed positive cytoplasmic and
nuclear staining in most tissue sections (arrows), with intense staining in 8 out of 44 samples, whereas EGFR membrane immunoreactivity (arrows) was
detected in 23 out of 44 cases (52.3%): 15.9% specimens showed high expression levels. (B) mRNA expression values of TS and EGFR observed across the
cohort of MPM patients, and correlation between TS (C) and EGFR (D) mRNA and protein expression. Values of mRNA and protein expression were
calculated as described in the Materials and Methods section. Data were analysed by both Student’s t and w2-test. Columns, mean values; bars, s.d.
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well as in EHMES-10 MPM cells harbouring a RET/PTC3
rearrangement (Ogino et al, 2008). Sensitivity to vandetanib in
the MPM cell lines also fell within the range of IC50 values
previously reported for other carcinoma cell lines, including
pancreas, breast, colon, gastric and ovarian cancer cells with
functional EGFR but lacking VEGFR-2 (Ciardiello et al, 2003;
Bianco et al, 2006). Furthermore, vandetanib interacted synergis-
tically with carboplatin, pemetrexed and their combination, and
increased the apoptotic fraction induced by the carboplatin–
pemetrexed combined treatment. These results are in agreement
with previous studies, showing enhanced apoptotic cell death after
combined treatment with vandetanib and paclitaxel, docetaxel,
gemcitabine or oxaliplatin in several cancer cell lines (Morelli et al,
2005; Yokoi et al, 2005; Bianco et al, 2006).
A phase II trial showed that non-small cell lung cancer (NSCLC)
patients receiving the triple combination of vandetanib, carboplatin
and paclitaxel had longer PFS compared with the control arm of
paclitaxelþ carboplatin (Heymach et al, 2008), while, in the phase
III ZEAL study, randomising 534 NSCLC patients to pemetrex-
edþ vandetanib or pemetrexedþ placebo as second-line treat-
ment, the addition of vandetanib failed to show an improvement in
PFS, but significantly improved RR (de Boer et al, 2011). To the
best of our knowledge, no clinical trials are currently evaluating
the addition of vandetanib to the carboplatin–pemetrexed regi-
men and hence no predictive biomarkers for clinical outcome for
this combination have been identified to date in MPM. Therefore,
the present study was also aimed at investigating the molecular
mechanisms underlying the synergistic interaction with peme-
trexed and carboplatin and exploring possible determinants/
biomarkers of drug activity (Figure 4).
By targeting the EGFR-dependent cancer cell proliferation and
the VEGFR-2-dependent tumour angiogenesis pathways, vandeta-
nib offers the potential advantages of blocking two key pathways in
different tumour types, namely cell proliferation and angiogenesis.
Several studies demonstrated that MPM is characterised by
dysregulation of molecular mechanisms involved in cell prolifera-
tion and angiogenesis (Zucali et al, 2011a, b). Malignant pleural
mesothelioma has one of the highest VEGF levels among solid
tumours (Linder et al, 1998), VEGFR-2 expression is detected in
most MPM samples (Nutt et al, 2009), and an increased
vascularisation is a poor prognostic factor (Edwards et al, 2003).
Therefore, small molecule inhibitors that target VEGFR-2 in both
vessels and tumour cells, such as vandetanib, may be useful for
MPM treatment. However, in agreement with previous findings
(Nutt et al, 2009), VEGFR-2 was not detectable in H28 cells, which
were the most sensitive to vandetanib, suggesting that other
pathways have a crucial role for vandetanib cytotoxicity. More-
over, vandetanib neither affected VEGF mRNA expression nor
VEGF secretion into the medium in our MPM cells, reflecting the
transient, inconsistent and relatively modest changes in plasma
VEGF after vandetanib treatment in patients (Hanrahan et al,
2010). Similarly, RET expression was not detectable in H28 and
MSTO-211H cells, suggesting that the modulation of this kinase is
not involved in drug activity in MPM cells lacking RET oncogenic
rearrangement, as described previously (Ogino et al, 2008).
Therefore, the activity of vandetanib seems limited to the
inhibition of EGFR and associated pathways. These findings are
in agreement with previous preclinical studies, showing a
prominent activity of EGFR inhibitors in mesothelioma cells (Nutt
et al, 2009; Stoppoloni et al, 2010; Barbieri et al, 2011). In
particular, in a study by Nutt et al (2009), which explored the
effects of five TKIs, vandetanib displayed the lowest IC50 values
across all the three MPM cell lines tested, including one cell line
that was positive for VEGFR-2 expression.
Epidermal growth factor receptor is a key driver of cell
proliferation, which was detected in all the cell lines and in the
majority of mesothelioma specimens in the present study, as well
as in previous studies (Destro et al, 2006; Gaafar et al, 2010).
Vandetanib significantly reduced EGFR phosphorylation, while
pemetrexed exposure resulted in a significant increase in phospho-
EGFR levels. These results are in agreement with previous data,
showing a schedule-dependent synergism of pemetrexed and the
EGFR-TKI erlotinib associated with pemetrexed-induced EGFR
phosphorylation (Li et al, 2007; Giovannetti et al, 2008). Similar
effects were observed for other cytotoxic drugs in NSCLC cells
displaying a synergistic interaction with gefitinib, as well as with
the TS-inhibitor 5-fluorouracil (5-FU) in colorectal cancer cells
(Van Schaeybroeck et al, 2005, 2006). In addition to the impact on
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Figure 4 Molecular signalling pathways and key determinants involved in the synergistic interaction of vandetanib with pemetrexed and carboplatin.
Vandetanib enhanced the growth inhibitory effects of cytotoxic drugs through its pronounced antisignalling effects downstream of EGFR. Furthermore, the
modulation of TS and DNA repair genes promotes pemetrexed and carboplatin activity.
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EGFR phosphorylation, downstream mediators of the EGFR
signalling pathway were affected not only by vandetanib but also
by pemetrexed and carboplatin, which reduced Akt phosphoryla-
tion. The Akt signalling pathway is frequently activated in MPM
and its inhibition increases drug sensitivity (Altomare et al, 2005).
Previous studies showed conflicting results regarding the modula-
tion of phospho-Akt levels by pemetrexed (Li et al, 2007;
Giovannetti et al, 2008), which may be related to the discrepancy
between drug exposure conditions and different sensitivities of
experimental methods. Our findings are in agreement with studies,
demonstrating reduced Akt phosphorylation after exposure to the
antimetabolite gemcitabine (Bianco et al, 2006; Feng et al, 2007). In
particular, Feng et al (2007) proposed a model of gemcitabine-
induced apoptosis via EGFR degradation, hence providing a
plausible mechanism by which a cytotoxic compound may affect
EGFR levels and Akt signalling pathways. Drug treatment through
c-Src activation leads to EGFR phosphorylation, which promotes
receptor ubiquitination. Epidermal growth factor receptor is then
targeted to lysosomes for degradation, thereby resulting in
downregulation of phospho-Akt. Since phospho-Akt regulates
antiapoptotic mechanisms and previous in vitro studies showed
that its downregulation by the pemetrexed–erlotinib combination
correlated with the enhancement of apoptosis and antitumour
activity in lung cancer cells (Giovannetti et al, 2008), the reduction
of phospho-Akt may explain the increased apoptosis after
pemetrexed–vandetanib and carboplatin–vandetanib combina-
tions in MPM cells.
The increased induction in apoptosis after the carboplatin–
vandetanib combination may also be related to DNA damage,
which was reported to be important for the efficacy of the
combination of EGFR-TKIs with different cytotoxic compounds,
including platinum derivatives (Morelli et al, 2005). Damage
induced by chemotherapy can convert EGFR ligands from growth
factors into survival factors for cancer cells that express functional
EGFR. In this context, the simultaneous blockade of EGFR
signalling after exposure to a cytotoxic drug such as carboplatin
could cause non-repairable damage thereby leading to apoptosis.
In addition to the effects on signalling pathways, the present
study shows that vandetanib also interfered with the cytotoxic
activity of pemetrexed and carboplatin. Indeed, vandetanib
significantly inhibited TS, the expression of which has been
recently correlated with outcome after pemetrexed-based regimens
in MPM (Righi et al, 2010; Zucali et al, 2011a, b). These data are in
accord with the previous observations that antitumour agents
other than antifolates and 5-FU also modulate TS levels.
As an RNA-binding protein, TS protein regulates its own
synthesis by blocking the translation of its own mRNA, and its
binding to a specific inhibitor leads to upregulation of TS protein
(Chu et al, 1991). In agreement with this hypothesis, as well as with
the observed increase in TS mRNA expression, as previously
detected after treatment with pemetrexed and 5-FU (Peters et al,
2002; Giovannetti et al, 2008), TS protein expression in cell extracts
was enhanced after pemetrexed exposure. However, other studies
reported that vinorelbine and irinotecan suppressed TS expression,
hence favouring the activity of 5-FU (Guichard et al, 1998;
Matsumoto et al, 2004). Thymidylate synthase expression and
activity was also decreased by EGFR-TKIs, thereby displaying
synergistic interaction with 50-deoxy-5-fluorouridine (Magne´ et al,
2003; Budman et al, 2006). In the latter study, it was postulated that
downregulation of TS was related to decrease in S-phase and
increase in G1-phase. However, the marginal increase in G1-phase
observed in the present study does not fit with this hypothesis, and
the effects on mRNA and protein expression suggest that TS
alterations are mediated by mechanisms involving transcriptional
regulation. In this regard, we detected a reduction of E2F-1 mRNA
expression after vandetanib exposure. These results may be
related to the nuclear effects of EGFR, which affect the
activity of several cell-cycle proteins and transcription factors,
including E2F-1 (Lo and Hung, 2006). High levels of free E2F-1
upregulate the transcription of several proliferation-associated
genes including TS (Huang et al, 2007). Epidermal growth
factor receptor-TKIs may affect E2F-1 directly or via downregula-
tion of cyclin D1 (Kobayashi et al, 2006; Suenaga et al, 2006). In this
regard, transfection of gastric cells with a cyclin D1 antisense
oligodeoxynucleotide reduced TS mRNA and significantly increased
5-FU and methotrexate sensitivity (Shuai et al, 2006).
However, the synergistic interaction with carboplatin is likely to be
mediated by the downregulation of ERCC1 and XPD expression,
which was found after exposure to both vandetanib and pemetrexed.
Due to the accelerated rate of DNA replication in neoplastic cells,
disruption of folate metabolism and consequent depletion of cellular
nucleotide pools causes impaired DNA synthesis and repair.
Furthermore, folate deficiency has been shown to act synergistically
with alkylating agents to increase DNA strand breaks and mutations
as a result of impaired DNA excision repair (Novakovic et al, 2006).
This effect may depend on the inhibition of gene expression of key
enzymes in DNA repair. In particular, our results demonstrated a
substantial reduction in the transcript levels of ERCC1 and XPD in all
MPM cell lines, as previously detected in a cisplatin-resistant
carcinoma cell line treated with 5-FU, as well as in colorectal cancer
cell lines treated with pemetrexed (Fujishima et al, 1997; Nannizzi
et al, 2010). Similarly, stimulation of oxaliplatin-DNA adduct
formation has previously been correlated with the potentiation of
oxaliplatin cytotoxicity by the anti-EGFR cetuximab in HCT-8
colorectal cancer cells. This upregulation was associated with
reduced expression of mRNA and protein levels of ERCC1 (Balin-
Gauthier et al, 2008).
Previous studies showed that cisplatin-induced increases in the
expression of ERCC1 following c-fos/c-jun and iAP-1-binding
activity (Rabo et al, 1996). In contrast, EGFR inhibition with
gefitinib/erlotinib abrogated the c-fos mRNA increase after
exposure to EGF (Jimeno et al, 2006), and EGFR inhibition with
gefitinib decreased the upregulation of c-Jun, Fos-B and AP-1
(Dougherty et al, 2008). Therefore, one can hypothesise that the
inhibition of these transcription factors by vandetanib is involved
in the downregulation of ERCC1.
In conclusion, the present study demonstrates that vandetanib
markedly enhances pemetrexed and carboplatin activity against
established MPM cell lines. Furthermore, we have characterised
several molecular mechanisms and key determinants associated with
these synergistic interactions. Vandetanib significantly reduced
EGFR, ERK1/2 and Akt phosporylation, as well as TS and ERCC1/
XPD expression, possibly via downregulation of the major transcrip-
tion factor E2F-1 and other transcription factors. No pharmacologic
activity was found on angiogenic signalling, with VEGFR-2 and RET
expression not even detectable in some cell lines, suggesting that
similar results might be observed with EGFR inhibitors. However, in
agreement with a previous study, vandetanib emerged as the
compound with the most potent cytotoxic activity (Nutt et al,
2009). Moreover, pemetrexed and carboplatin increased EGFR
phosphorylation and reduced Akt phosphorylation, which was
further reduced by drug combination, and induced a marked
apoptosis. The positive modulation of these key determinants of
antitumour drug activity, as well as the detection of their expression
in MPM samples, whose variability should be evaluated for possible
patients’ stratification in future trials, warrant further preclinical and
clinical studies for the rational development of combination
chemotherapeutic regimens including vandetanib as an integral
component in the treatment of MPM.
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